NCT00412243View on ClinicalTrials.gov

Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Burkitt's LymphomaLymphoblastic LymphomaAcute Lymphoblastic Leukemia
Interventions
DRUG

Clofarabine

40 mg/m\^2 Daily for 3 Days

DRUG

Cyclophosphamide

Beginning dose 200 mg/m\^2 every 12 hours for 3 days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00412243 - Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | Biotech Hunter | Biotech Hunter